In a landmark moment for patients with ultra-rare mitochondrial diseases, the US Food & Drug Administration (FDA) has approved the first-ever drug to treat Thymidine Kinase 2 Deficiency (TK2d). The ...
(RTTNews) - According to results from a multicenter study published by Neurology, UCB SA (UCBJY) showed on Monday, that its investigational pyrimidine nucleoside therapy has the potential to greatly ...
Thymidine kinase 2 deficiency (TK2d) is a very rare genetic disease that causes muscle weakness, which can happen in different parts of your body. TK2d can sometimes be severe and affect your ability ...
Kygevvi is expected to be commercially available in the US in the first quarter of 2026. The Food and Drug Administration (FDA) has approved Kygevvi ® for the treatment of thymidine kinase 2 ...